Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golimumab Safety and Efficacy in Indian Patients with AS or PsA
NCT03733925Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 2019
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of golimumab in ankylosing spondylitis (AS), psoriatic arthritis (PsA), sponsored by Johnson & Johnson. Started Jan 2019; status: completed.
02
Drugs
golimumab
03
Conditions
ankylosing spondylitis (AS)psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03733925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733925.